DE10315025A1 - Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use - Google Patents

Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use Download PDF

Info

Publication number
DE10315025A1
DE10315025A1 DE10315025A DE10315025A DE10315025A1 DE 10315025 A1 DE10315025 A1 DE 10315025A1 DE 10315025 A DE10315025 A DE 10315025A DE 10315025 A DE10315025 A DE 10315025A DE 10315025 A1 DE10315025 A1 DE 10315025A1
Authority
DE
Germany
Prior art keywords
diseases
active ingredient
oil
ingredient combination
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10315025A
Other languages
German (de)
Inventor
Egon Dr. Koch
Karl-Heinz Dr. Stumpf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioplanta Arzneimittel GmbH
Original Assignee
Bioplanta Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplanta Arzneimittel GmbH filed Critical Bioplanta Arzneimittel GmbH
Priority to DE10315025A priority Critical patent/DE10315025A1/en
Priority to CA002521040A priority patent/CA2521040A1/en
Priority to EP04724578A priority patent/EP1608387A2/en
Priority to PCT/EP2004/003401 priority patent/WO2004087181A2/en
Priority to BRPI0409139-6A priority patent/BRPI0409139A/en
Priority to MXPA05010416A priority patent/MXPA05010416A/en
Priority to RU2005130342/15A priority patent/RU2005130342A/en
Publication of DE10315025A1 publication Critical patent/DE10315025A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft Wirkstoffkombinationen von omega3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung zur Behandlung entzündlicher und/oder immunologischer und metabolischer Erkrankungen sowie anderer Leiden.The present invention relates to active ingredient combinations of omega-3 fatty acid oils with polyphenol-containing plant extracts and their use for the treatment of inflammatory and / or immunological and metabolic diseases and other conditions.

Description

Die vorliegende Erfindung betrifft Wirkstoffkombinationen von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung zur Behandlung entzündlicher und/oder immunologischer und metabolischer Erkrankungen sowie anderer Leiden.The The present invention relates to combinations of active substances containing ω3-fatty acid oils Plant extracts containing polyphenols and their use for treatment inflammatory and / or immunological and metabolic diseases and others Suffer.

Zahlreiche experimentelle und klinische Studien belegen, dass ω3-Fettsäuren den Krankheitsprozess bei chronischen entzündlichen und/oder immunologischen Erkrankungen, wie z. B. Atherosklerose, koronarer Herzerkrankung, rheumatoider Arthritis, Psoriasis etc. günstig beeinflussen. Außerdem wird berichtet, dass diese Fettsäuren über präventive und protektive Effekte bei Fettstoffwechselstörungen oder Diabetes vertilgen und deshalb zur Behandlung von vaskulären und neurologischen Störungen, wie sie bei diesen Erkrankungen auftreten, geeignet sind. Bei einem Mangel von ω3-Fettsäuren in der Nahrung wurden visuelle und zentralnervöse Störungen sowie hämorrhagische Dermatitis, Wachstumsstörungen und eine verzögerte Wundheilung beobachtet. Da der Säugerorganismus nicht in der Lage ist, diese Verbindungen selbst zu synthetisieren, ist er auf die Zufuhr mit der Nahrung angewiesen.numerous experimental and clinical studies prove that ω3 fatty acids Disease process in chronic inflammatory and / or immunological Diseases such as B. atherosclerosis, coronary heart disease, favorably affect rheumatoid arthritis, psoriasis etc. Besides, will reports that these fatty acids are preventive and protective effects in fat metabolism disorders or diabetes and therefore for the treatment of vascular and neurological disorders, as they occur in these diseases are suitable. At a Deficiency of ω3 fatty acids in visual and central nervous disorders, as well as hemorrhagic disorders Dermatitis, growth disorders and a delayed Wound healing observed. Because the mammal organism is unable to synthesize these compounds itself, he is dependent on food.

Die beobachteten günstigen Effekte von ω3-Fettsäuren werden damit erklärt, dass diese Substanzen die Bildung von proinflammatorischen Prostaglandinen und Leukotrienen aus Arachidonsäure verhindern, indem sie diese Fettsäure aus ihrer Bindung in der SN2-Position von Phospholipiden der Zellmembranen verdrängen.The observed favorable Effects of ω3 fatty acids will be thus explained that these substances prevent the formation of pro-inflammatory prostaglandins and leukotrienes from arachidonic acid prevent this fatty acid from binding in it Displace the SN2 position of phospholipids in the cell membranes.

Mehrfach ungesättigte Fettsäuren wie z. B. α-Linolensäure, Eikosapentaensäure oder Docosahexaensäure sind extrem oxidationsempfindlich. Die Inkorporation solcher Fettsäuren oder ihrer Folgeprodukte in zellulären Membranen erhöht deshalb den Bedarf des Organismus an Antioxidantien.Multiple unsaturated fatty acids such as B. α-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid are extremely sensitive to oxidation. The incorporation of such fatty acids or of their progeny in cellular Membranes increased hence the organism's need for antioxidants.

Epidemiologische Studien haben gezeigt, dass der Verzehr von polyphenolreichen Lebensmitteln mit einer verringerten Rate von kardiovaskulären Erkrankungen, Krebs, Osteoporose, Tumorleiden etc. verbunden ist. Die Bezeichnung Polyphenole umfasst einfache Phenolcarbonsäuren wie z. B. Gentisinsäure, Protocatechusäure, Gallussäure oder Kaffeesäure, weiterhin Flavone wie z. B. Kämpferol, Quercetin, Myricetin, Isorhamnetin, Naringenin, 6-Prenylnaringenin, 8-Prenylnaringenin, Isoxanthohumol und deren Glykoside, Chalkone wie z. B. Xanthohumol, Isoflavone wie z. B. Daidzein und Genistein, Anthocyane wie z. B. Pelargonidin, Cyanidin, Malvidin oder Delphinidin, Gerbstoffe wie z. B. Catechin und Epicatechin, deren Oligomere und Polymere sowie Lignane. Alle diese Verbindungen sind reduzierende Agentien und tragen zusammen mit anderen antioxidativen Substanzen, z. B. Vitamin C und E, zum Schutz des Körpers gegen oxidativen Stress bei. Mit oxidativem Stress wird ein Zustand im Körper bezeichnet, bei dem die Bildung von Oxidantien und freien Radikalen die Fähigkeit des Körpers übersteigt, diese Stoffe zu inaktivieren. Als Folge kommt es zu Schädigungen von Proteinen, DNA und Lipiden sowie von Zellmembranen und anderen Strukturelementen. Es ist heute allgemein akzeptiert, dass Oxidationsprodukte an der Entstehung verbreiteter Erkrankungen wie Atherosklerose, chronischen Entzündungen, Krebs oder Diabetes beteiligt sind und den Alterungsprozess beschleunigen. Die Menge freier Radikale hängt vom Lebensstil (Ernährung, Rauchen, Bewegung) ab und wird durch gleichzeitig bestehende Erkrankungen beeinflusst (z. B. Hypercholesterinämie, Diabetes). Eine besonders reiche Quelle von Sauerstoffradikalen sind z. B. neutrophile Granulozyten, die diese Verbindungen bei Entzündungsreaktionen freisetzen. Da endogen gebildete antioxidativ wirkende Moleküle bzw. Enzyme in ihrer Konzentration oder Aktivität nicht durch exogene Maßnahmen beeinflusst werden können, kommt der Zufuhr von Antioxidantien über die Ernährung eine entscheidende Bedeutung zu.epidemiological Studies have shown that eating polyphenol-rich foods with a reduced rate of cardiovascular disease, cancer, osteoporosis, Tumor disease etc. is connected. The term polyphenols includes simple phenolic carboxylic acids such as B. gentisic acid, protocatechuic, gallic acid or caffeic acid, still flavones such as B. militant, Quercetin, myricetin, isorhamnetin, naringenin, 6-prenylnaringenin, 8-prenylnaringenin, isoxanthohumol and their glycosides, chalcones such as B. xanthohumol, isoflavones such as. B. Daidzein and Genistein, Anthocyanins such as B. pelargonidine, cyanidin, malvidin or delphinidin, Tannins such as B. catechin and epicatechin, their oligomers and Polymers and lignans. All of these compounds are reducing Agents and contribute along with other antioxidant substances, z. As vitamins C and E, to protect the body against oxidative stress at. Oxidative stress is a condition in the body in which the Formation of oxidants and free radical ability of the body, to inactivate these substances. As a result, damage occurs of proteins, DNA and lipids as well as of cell membranes and others Structural elements. It is now widely accepted that oxidation products in the development of common diseases such as atherosclerosis, chronic inflammation, Cancer or diabetes are involved and accelerate the aging process. The amount of free radicals depends lifestyle (nutrition, Smoking, exercise) and is caused by existing diseases influenced (e.g. hypercholesterolemia, diabetes). A special one Rich sources of oxygen radicals are e.g. B. neutrophilic granulocytes, which these compounds in inflammatory reactions release. Since endogenously formed molecules with an antioxidative effect or Enzymes in their concentration or activity are not exogenous can be influenced the supply of antioxidants through nutrition is of crucial importance to.

Aufgabe der vorliegenden Erfindung ist es, Mittel zur Prävention und Behandlung entzündlicher und immunologischer Erkrankungen sowie von Tumorleiden bereitzustellen.task The present invention is to prevent and treat inflammatory agents and immunological diseases as well as tumor diseases.

Diese Aufgabe wird gelöst durch eine Wirkstoffkombination, umfassend mindestens ein ω3-fettsäurehaltiges Öl und mindestens einen polyphenolhaltigen Pflanzenextrakt, wobei diese gleichzeitig einen Mangel an ω3-Fettsäuren und an antioxidativen Polyphenolen ausgleicht, einem solchen Mangel vorbeugt oder einen erhöhten Bedarf dieser Substanzen bei entzündlichen und/oder immunologischen sowie metabolischen Erkrankungen und Tumorleiden abdeckt.This Task is solved by a combination of active ingredients comprising at least one ω3-fatty oil and at least one a polyphenol-containing plant extract, this at the same time a lack of ω3 fatty acids and of antioxidant polyphenols, such a deficiency prevents or an elevated Need of these substances in inflammatory and / or immunological as well as metabolic diseases and tumor diseases.

Diese Wirkstoffkombination wirkt durch die Hemmung der Produktion von proinflammatorischen Eicosanoiden und der Neutralisation von freien Radikalen gleichzeitig zwei wichtigen an der Pathogenese von Entzündungsreaktionen und Stoffwechselerkrankungen beteiligten Faktoren entgegen. Außerdem hat sie den Vorteil, dass die oxidationsempfindlichen ω3-Fettsäuren durch die antioxidative Wirkung der Polyphenole und/oder Vitamine sowohl bei der Lagerung als auch nach der Inkorporation in Zellmembranen vor einer Degradation geschützt werden.This combination of active ingredients works by inhibiting the production of pro-inflammatory eico sanoids and the neutralization of free radicals simultaneously oppose two important factors involved in the pathogenesis of inflammatory reactions and metabolic diseases. It also has the advantage that the oxidation-sensitive ω3 fatty acids are protected against degradation by the antioxidative action of the polyphenols and / or vitamins both during storage and after incorporation in cell membranes.

Eine bevorzugte ω3-Fettsäure ist α-Linolensäure, die beispielsweise zu etwa 50 – 60 % im Öl aus den Samen von Perilla frutescens (Perillaöll) enthalten ist. Aus diesem Grund ist Perillaöl ein bevorzugtes ω3-fettsäurehaltiges Öl. Weitere Beispiele von geeigneten Ölen umfassen Borretschöl, Nachtkerzensamenöl, Fischöl, Johannisbeerkernöl und Leinöl.A preferred ω3 fatty acid is α-linolenic acid for example about 50-60 % in oil from the seeds of Perilla frutescens (perilla oil). For this The reason is perilla oil a preferred ω3 fatty acid oil. Further Examples of suitable oils include borage oil, Evening primrose oil, Fish oil, Currant seed oil and linseed oil.

Figure 00030001
Figure 00030001

Bevorzugte polyphenolhaltige Pflanzenextrakte sind Extrakte aus Aspalathus linearis, Crataegus-Arten, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, Theobroma cacao, Vaccinium myrtillus und Vitis vinifera. Die Erfindung ist jedoch nicht auf die genannten Pflanzen beschränkt. Der polyphenolhaltige Pflanzenextrakt enthält vorzugsweise mindestens 15 Gw.% Polyphenole, bezogen auf den Trockenextrakt.preferred Plant extracts containing polyphenols are extracts from Aspalathus linearis, Crataegus species, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, Theobroma cacao, Vaccinium myrtillus and Vitis vinifera. However, the invention is not limited to the plants mentioned. The Plant extract containing polyphenol preferably contains at least 15% by weight of polyphenols, based on the dry extract.

Bevorzugt sind Wirkstoffkombinationen, die eine der nachfolgenden Kombinationen enthalten: Extrakt aus Vitis vinifera und Perillasamenöl, Extrakt aus Vaccinium myrtillus und Leinöl, Extrakt aus Ginkgo biloba und Leinöl, Extrakt aus Crataegus und Borretschöl, Extrakt aus Aspalathus linearis und Borretschöl, Extrakt aus Theobroma cacao und Nachtkerzensamenöl, Extrakt aus Tabebuia avellanedae und Nachtkerzensamenöl, Extrakt aus Hypericum perforatum und Fischöl, Extrakt aus Humulus lupulus und Fischöl, Extrakt aus Paullinia cupana und Johannisbeerkernöl, Extrakt aus Rubus idaeus und Johannisbeerkernöl, Extrakt aus Rubus fructicosus und Perillasamenöl, Extrakt aus Aspalathus linearis und Perillasamenöl sowie Extrakt aus Humulus lupulus und Perillasamenöl.Prefers are combinations of active ingredients that are one of the following combinations contain: extract from Vitis vinifera and perilla seed oil, extract from Vaccinium myrtillus and linseed oil, Ginkgo biloba extract and linseed oil, Crataegus and Borage oil, Aspalathus linearis extract and borage oil, Theobroma cacao extract and evening primrose seed oil, Extract from Tabebuia avellanedae and evening primrose seed oil, extract from Hypericum perforatum and fish oil, extract from Humulus lupulus and fish oil, Extract from Paullinia cupana and currant seed oil, extract from Rubus idaeus and currant seed oil, extract from Rubus fructicosus and perilla seed oil, Extract from Aspalathus linearis and perilla seed oil as well as extract from Humulus lupulus and perilla seed oil.

Die Extrakte können nach an sich bekannten Herstellungsverfahren in variabler Zusammensetzung mit Lösungsmitteln wie z. B. Wasser, Methanol, Ethanol, 2-Propanol, Aceton, etc und Gemischen davon bei Temperaturen von Raumtemperaturen bis 100°C unter gelinder bis heftiger Durchmischung oder durch Perkolation innerhalb von 10 Min. bis 24 Std. unter Normaldruck oder erhöhtem Druck erhalten werden. Zur Anreicherung von wirksamkeitsrelevanten Komponenten können weitere Konzentrierungsschritte durchgeführt werden, wie z. B. Flüssig-Flüssig-Verteilung mit z. B. 1-Butanol/Wasser oder Ethylacetat/Wasser, Adsorption-Desorption an Ionenaustauscher, LH20, HP20 und andere Harze oder chromatographische Abtrennungen über RP18, Kieselgel, etc. Die Weiterverarbeitung zu Trockenextrakten erfolgt nach an sich bekannten Verfahren durch Abziehen des Lösungsmittels bei erhöhter Temperatur und/oder reduziertem Druck.The Extracts can according to known manufacturing processes in a variable composition solvents such as B. water, methanol, ethanol, 2-propanol, acetone, etc and Mixtures of these at temperatures from room temperatures to 100 ° C with mild to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure can be obtained. Additional components can be added to enrich the effectiveness-related components Concentration steps carried out be such. B. Liquid-liquid distribution with z. B. 1-butanol / water or ethyl acetate / water, adsorption-desorption on ion exchangers, LH20, HP20 and other resins or chromatographic Partitions via RP18, Silica gel, etc. The further processing to dry extracts takes place by methods known per se by stripping off the solvent with increased Temperature and / or reduced pressure.

Die erfindungsgemäßen Wirkstoffkombinationen können zur Behandlung, zur Unterstützung der Behandlung oder zur Prophylaxe von entzündlichen und/oder immunologischen sowie metabolischen Erkrankungen und anderer Leiden, wie z. B. rheumatoider Arthritis, Polyarthritis, Synovitis, Akne, Neurodermitis, Psoriasis, Asthma, Heuschnupfen, Atherosklerose, koronarer Herzerkrankungen oder Herzrhythmusstörungen, von chronischen Darmerkrankungen, wie z. B. ulzerative Colitis oder Crohnsche Krankheit, sowie von Polyneuropathien, Retinopathien, cerebralen und peripheren arteriellen Durchblutungsstörungen, psychiatrischen Erkrankungen, wie z. B. Depression, Schizophrenie, bipolare Disorder, und von Tumorerkrankungen eingesetzt werden. Dabei ist diese Liste der Erkrankungen, deren Entstehung und Verlauf durch die Verwendung der erfindungsgemäßen Kombination von ω3-fettsäurehaltigem Öl mit polyphenolhaltigen Pflanzenextrak ten günstig beeinflusst werden kann, aber nicht als erschöpfend anzusehen. Die erfindungsgemäße Wirkstoffkombination kann in Form eines diätetischen Nahrungsmittels oder Arzneimittels vorliegen.The Active ingredient combinations according to the invention can for treatment, for support the treatment or prophylaxis of inflammatory and / or immunological as well as metabolic diseases and other conditions such as B. rheumatoid Arthritis, polyarthritis, synovitis, acne, neurodermatitis, psoriasis, Asthma, hay fever, atherosclerosis, coronary heart disease or irregular heartbeat, of chronic bowel diseases such as B. ulcerative colitis or Crohn's disease, as well as polyneuropathies, retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders such as B. depression, schizophrenia, bipolar disorder, and used by tumor diseases. Here is this list of diseases, their emergence and course by using the combination of ω3-fatty acid-containing oil with polyphenol-containing oil according to the invention Plant extracts favorably influenced can be considered but not exhaustive. The active ingredient combination according to the invention can in the form of a dietary Food or drug.

Die erfindungsgemäßen Wirkstoffkombinationen werden bevorzugt im Rahmen einer bilanzierten Diät verabreicht. Den Wirkstoffkombinationen können zusätzliche Komponenten wie z. B. Vitamin C und/oder E zugesetzt werden, um auch deren Mangel auszugleichen oder deren erhöhten Bedarf sicherzustellen.The Active ingredient combinations according to the invention are preferably administered as part of a balanced diet. The active ingredient combinations can additional Components such as B. Vitamin C and / or E can be added to also to compensate for their deficiency or to ensure their increased need.

Als fließfähige Mischungen meist pulverförmiger Pflanzenextrakte mit lipophilen Pflanzenölen sind die erfindungsgemäßen Wirkstoffkombinationen gut zur Abfüllung in Kapseln geeignet. Gegebenenfalls können weitere Stoffe wie z. B. partiell oder vollständig hydrierte Pflanzenöle, Bienenwachs, Lecithin, Neutralöl, Hartfett und hochdisperses Siliciumdioxid zur Kapselfüllmasse hinzugefügt werden, um die Konsistenz der Mischungen einzustellen und eine Entmischung von flüssiger Komponente und festem Pflanzenextrakt zu verhindern. Um die Auflösung des aus der Kapsel freigesetzten Kapselinhaltes zu beschleunigen, können auch amphiphile, oberflächenaktive Substanzen und Emulgatoren wie z. B. Sorbitanmonooleat zugefügt werden.As flowable mixtures of mostly powdered plant extracts with lipophilic vegetable oils, the active compound combinations according to the invention are well suited for filling in capsules. If necessary, other substances such. B. partially or fully hydrogenated vegetable oils, beeswax, lecithin, neutral oil, hard fat and highly disperse silicon dioxide can be added to the capsule filling mass to ensure the consistency of the Mi and to prevent segregation of the liquid component and solid plant extract. In order to accelerate the dissolution of the capsule contents released from the capsule, amphiphilic, surface-active substances and emulsifiers such as. B. Sorbitan monooleate can be added.

Der Pflanzenextrakt wird mit dem Öl (beide gemäß nachstehender Tabelle) gemischt und die erhaltene fließfähige Suspension wird mit einem geeigneten Verfahren in Kapseln abgefüllt.The Plant extract comes with the oil (both according to the following Table) mixed and the flowable suspension obtained with a suitable methods filled into capsules.

Beispiel 1

Figure 00050001
example 1
Figure 00050001

Beispiel 2

Figure 00060001
Example 2
Figure 00060001

Beispiel 3

Figure 00060002
Example 3
Figure 00060002

Die in den vorausgehenden Beispielen beschriebenen Kombinationen von ω3-fettsäurehaltigen Ölen und polyphenolhaltigen Pflanzenextrakten zeichnen sich dadurch aus, dass sie die Synthese von proinflammatorischen Eicosanoiden und die Neutralisation von freien Radikalen hemmen. Außerdem haben sie den Vorteil, dass die oxidationsempfindlichen ω3-Fettsäuren durch die antioxidative Wirkung der Polyphenole sowohl bei der Lagerung als auch nach der Inkorporation in Zellmembranen vor einer Degradation geschützt werden.The Combinations of ω3 fatty acid oils and. described in the previous examples Plant extracts containing polyphenol are characterized by that they are the synthesis of proinflammatory eicosanoids and inhibit the neutralization of free radicals. Also have they have the advantage that the oxidation-sensitive ω3 fatty acids the antioxidant effect of the polyphenols both during storage as well as after incorporation in cell membranes before degradation protected become.

Claims (13)

Wirkstoffkombination, umfassend mindestens ein ω3-fettsäurehaltiges Öl und mindestens einen polyphenolhaltigen Pflanzenextrakt.Active ingredient combination comprising at least one ω3-fatty acid-containing oil and at least a plant extract containing polyphenols. Wirkstoffkombination nach Anspruch 1, wobei das ω3-fettsäurehaltige Öl α-Linolensäure enthält.Active ingredient combination according to claim 1, wherein the ω3-fatty acid-containing oil contains α-linolenic acid. Wirkstoffkombination nach Anspruch 2, wobei das ω3-fettsäurehaltige Öl ausgewählt ist aus der Gruppe umfassend Perillasamenöl, Borretschöl, Nachtkerzensamenöl, Fischöl, Leinöl und Johannisbeerkernöl.Active ingredient combination according to claim 2, wherein the ω3-fatty acid-containing oil is selected from the group comprising perilla seed oil, borage oil, evening primrose seed oil, fish oil, linseed oil and currant seed oil. Wirkstoffkombination nach einem der Ansprüche 1 bis 3, wobei der polyphenolhaltige Pflanzenextrakt mindestens 15 Gw.-% Polyphenole, bezogen auf den Trockenextrakt, enthält.Active ingredient combination according to one of claims 1 to 3, the polyphenol-containing plant extract at least 15% by weight Contains polyphenols, based on the dry extract. Wirkstoffkombination nach einem der Ansprüche 1 bis 4, wobei der polyphenolhaltige Pflanzenextrakt ein Extrakt aus Aspalathus linearis, Crataegus-Arten, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, Theobroma cacao, Vaccinium myrtillus oder Vitis vinifera ist.Active ingredient combination according to one of claims 1 to 4, the polyphenol-containing plant extract being an extract from Aspalathus linearis, Crataegus species, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, Theobroma cacao, Vaccinium myrtillus or Vitis vinifera is. Verwendung von Wirkstoffkombinationen nach einem der Ansprüche 1 bis 5 zur Behandlung, zur Unterstützung der Behandlung oder zur Prophylaxe von entzündlichen und/oder immunologischen sowie metabolischen Erkrankungen und anderer Leiden, ausgewählt aus der Gruppe umfassend chronische Darmerkrankungen, Polyneuropathien, Retinopathien, cerebrale und periphere arterielle Durchblutungsstörungen, psychiatrische Erkrankungen und Tumorerkrankungen.Use of active substance combinations according to one of claims 1 to 5 for the treatment, to support the treatment or for the prophylaxis of inflammatory and / or immunological and metaboli diseases and other ailments selected from the group comprising chronic intestinal diseases, polyneuropathies, retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric diseases and tumor diseases. Verwendung nach Anspruch 6, wobei die entzündlichen und/oder immunologischen sowie metabolischen Erkrankungen ausgewählt sind aus der Gruppe umfassend rheumatoide Arthritis, Polyarthritis, Synovitis, Akne, Neurodermitis, Psoriasis, Asthma, Heuschnupfen, Atherosklerose, koronare Herzerkrankungen und Herzrhythmusstörungen.Use according to claim 6, wherein the inflammatory and / or immunological and metabolic diseases are selected from the group comprising rheumatoid arthritis, polyarthritis, synovitis, Acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary artery disease and arrhythmia. Verwendung nach Anspruch 6, wobei die chronischen Darmerkrankungen ausgewählt sind aus der Gruppe umfassend ulzerative Colitis und Crohnsche Krankheit.Use according to claim 6, wherein the chronic Bowel diseases selected are from the group consisting of ulcerative colitis and Crohn's disease. Verwendung nach Anspruch 6, wobei die psychiatrischen Erkrankungen ausgewählt sind aus der Gruppe umfassend Depression, Schizophrenie und bipolare Disorder.Use according to claim 6, wherein the psychiatric Selected diseases are from the group including depression, schizophrenia and bipolar Disorder. Diätetisches Nahrungsmittel oder Arzneimittel, enthaltend die Wirkstoffkombination nach einem der Ansprüche 1 bis 5 zur Behandlung oder zur Unterstützung der Behandlung von entzündlichen oder immunologischen Erkrankungen, von chronischen Darmerkrankungen sowie von Polyneuropathien, Retinopathien, cerebralen und peripheren arteriellen Durchblutungsstörungen, psychiatrischen Erkrankungen und von Tumorerkrankungen.dietetic Food or drugs containing the combination of active ingredients according to one of the claims 1 to 5 to treat or support the treatment of inflammatory or immunological diseases, from chronic bowel diseases as well as polyneuropathies, retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders and tumor diseases. Verwendung einer Wirkstoffkombination nach einem der Ansprüche 1 bis 5 zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen und/oder immunologischen sowie metabolischen Erkrankungen und anderer Leiden, ausgewählt aus der Gruppe umfassend chronische Darmerkrankungen sowie Polyneuropathien, Retinopathien, cerebrale und periphere arterielle Durchblutungsstörungen, psychiatrische Erkrankungen und Tumorleiden.Use of an active ingredient combination after a of claims 1 to 5 for the manufacture of a medicament for the treatment of inflammatory and / or immunological and metabolic diseases and others Suffering, selected from the group comprising chronic bowel diseases and polyneuropathies, Retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders and tumor disorders. Verwendung einer Wirkstoffkombination nach einem der Ansprüche 1 bis 5 zur Herstellung eines diätetischen Nahrungsmittels zur Behandlung oder zur Unterstützung der Behandlung von entzündlichen und/oder immunologischen und metabolischen Erkrankungen sowie anderer Leiden, ausgewählt aus der Gruppe umfassend chronische Darmerkrankungen sowie Polyneuropathien, Retinopathien, cerebrale und periphere arterielle Durchblutungsstörungen, psychiatrische Erkrankungen und Tumorleiden.Use of an active ingredient combination after a of claims 1 to 5 for the preparation of a dietary Food to treat or support the treatment of inflammatory and / or immunological and metabolic diseases and other conditions, selected from the group comprising chronic bowel diseases and polyneuropathies, Retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders and tumor disorders. Zubereitung, umfassend eine Wirkstoffkombination nach einem der Ansprüche 1 bis 5 und geeignete Hilfsstoffe als orale Darreichungsform.Preparation comprising a combination of active ingredients according to one of the claims 1 to 5 and suitable excipients as an oral dosage form.
DE10315025A 2003-04-02 2003-04-02 Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use Withdrawn DE10315025A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE10315025A DE10315025A1 (en) 2003-04-02 2003-04-02 Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use
CA002521040A CA2521040A1 (en) 2003-04-02 2004-03-31 Active ingredient combinations of plant oils containing .omega.3-fatty acids and plant extracts containing polyphenols and the use thereof
EP04724578A EP1608387A2 (en) 2003-04-02 2004-03-31 ACTIVE INGREDIENT COMBINATIONS OF PLANT OILS CONTAININGw3-FATTY ACIDS AND PLANT EXTRACTS CONTAINING POLYPHENOLS AND THE USE THEREOF
PCT/EP2004/003401 WO2004087181A2 (en) 2003-04-02 2004-03-31 ACTIVE INGREDIENT COMBINATIONS OF PLANT OILS CONTAINING ω3-FATTY ACIDS AND PLANT EXTRACTS CONTAINING POLYPHENOLS AND THE USE THEREOF
BRPI0409139-6A BRPI0409139A (en) 2003-04-02 2004-03-31 combination of active ingredients of w3 fatty acid-containing oils with polyphenol-containing plant extracts and use of these
MXPA05010416A MXPA05010416A (en) 2003-04-02 2004-03-31 ACTIVE INGREDIENT COMBINATIONS OF PLANT OILS CONTAINING omega3-FATTY ACIDS AND PLANT EXTRACTS CONTAINING POLYPHENOLS AND THE USE THEREOF.
RU2005130342/15A RU2005130342A (en) 2003-04-02 2004-03-31 COMBINATION OF ACTIVE INGREDIENTS OF OILS CONTAINING W3-FATTY ACIDS, WITH VEGETABLE EXTRACTS CONTAINING POLYPHENOLS, AND THEIR APPLICATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10315025A DE10315025A1 (en) 2003-04-02 2003-04-02 Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use

Publications (1)

Publication Number Publication Date
DE10315025A1 true DE10315025A1 (en) 2004-10-14

Family

ID=32980960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10315025A Withdrawn DE10315025A1 (en) 2003-04-02 2003-04-02 Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use

Country Status (7)

Country Link
EP (1) EP1608387A2 (en)
BR (1) BRPI0409139A (en)
CA (1) CA2521040A1 (en)
DE (1) DE10315025A1 (en)
MX (1) MXPA05010416A (en)
RU (1) RU2005130342A (en)
WO (1) WO2004087181A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005035864A1 (en) * 2005-07-30 2007-02-01 Beiersdorf Ag Use of xanthohumol or isoxanthohumol to prepare cosmetic or dermatological compositions for treating or preventing symptoms of skin aging and the harmful effects of ultraviolet radiation on the skin
DE102006033321A1 (en) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medical use of N-phenylpropenoyl amino acid derivatives and related compounds
FR2912918A1 (en) * 2007-02-27 2008-08-29 Persee Medica Soc Par Actions Use of polyunsaturated fatty acids and flavonoids, as active agent for simultaneous, sequential or separate use for the preparation of a composition for the prevention and/or treatment of headache
US8257751B2 (en) * 2003-11-03 2012-09-04 Beauté Pacifique ApS Composition for the cosmetic treatment of age-related dermatological symptoms
CN109316535A (en) * 2017-07-31 2019-02-12 格特生物制药（天津）有限公司 A kind of Chinese medicine composition and preparation method thereof for treating chicken synovitis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407667T1 (en) * 2003-04-08 2008-09-15 Kirin Brewery COMPOSITION FOR INHIBITING OR PREVENTING THE DECREASE IN BONE DENSITY
FR2885528A1 (en) * 2005-05-13 2006-11-17 Persee Medica COMPOSITION USEFUL FOR TREATING OR PREVENTING DISORDERS ASSOCIATED WITH DERIVATION OF BIOLOGICAL CLOCK
GB0719545D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719544D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
GB0719542D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
EP2133088A3 (en) * 2008-06-09 2010-01-27 Nestec S.A. Rooibos and inflammation
EP2135616B1 (en) * 2008-06-19 2016-05-04 Symrise AG Dried bilberries for influencing intestinal conditions
US20170027902A1 (en) * 2014-04-11 2017-02-02 George Robertson Use of a Composition Comprising a Flavonol, A Flavonoid, and a Fatty Acid in the Treatment of Oxidative Injuries Due to Mitochondrial Dysfunction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0558901A (en) * 1991-08-26 1993-03-09 Teikoku Hormone Mfg Co Ltd Bone desorption-inhibiting factor and its production
FR2770974A1 (en) * 1997-11-20 1999-05-21 Hatem Smaoui Plant-based food supplement contains oils which are rich in omega fatty acids and anti-free radical agents
DE10315027A1 (en) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Capsules with delayed release of the capsule contents for oral administration
DE10315026A1 (en) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Compositions containing omega-3 fatty acid oils and plant extracts

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257751B2 (en) * 2003-11-03 2012-09-04 Beauté Pacifique ApS Composition for the cosmetic treatment of age-related dermatological symptoms
DE102005035864A1 (en) * 2005-07-30 2007-02-01 Beiersdorf Ag Use of xanthohumol or isoxanthohumol to prepare cosmetic or dermatological compositions for treating or preventing symptoms of skin aging and the harmful effects of ultraviolet radiation on the skin
DE102006033321A1 (en) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medical use of N-phenylpropenoyl amino acid derivatives and related compounds
FR2912918A1 (en) * 2007-02-27 2008-08-29 Persee Medica Soc Par Actions Use of polyunsaturated fatty acids and flavonoids, as active agent for simultaneous, sequential or separate use for the preparation of a composition for the prevention and/or treatment of headache
WO2008122723A2 (en) * 2007-02-27 2008-10-16 Persee Medica Use of poly-unsaturated fatty acids and flavonoids as active ingredients in a composition for preventing and/or treating migraines
WO2008122723A3 (en) * 2007-02-27 2009-01-22 Persee Medica Use of poly-unsaturated fatty acids and flavonoids as active ingredients in a composition for preventing and/or treating migraines
CN109316535A (en) * 2017-07-31 2019-02-12 格特生物制药（天津）有限公司 A kind of Chinese medicine composition and preparation method thereof for treating chicken synovitis

Also Published As

Publication number Publication date
WO2004087181A3 (en) 2005-04-21
BRPI0409139A (en) 2006-03-28
RU2005130342A (en) 2006-03-27
MXPA05010416A (en) 2006-03-21
WO2004087181A2 (en) 2004-10-14
WO2004087181A8 (en) 2004-12-29
EP1608387A2 (en) 2005-12-28
CA2521040A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
AT407821B (en) MEDIUM BASED ON NATURAL SUBSTANCES
DE60122196T2 (en) SYNERGISTIC ANTIOXIDANE COMBINATION BY DELTA TOCOLS AND POLYPHENOLES
DE60012709T2 (en) FOOD SUPPLEMENT AND METHOD FOR COSMETIC TREATMENT USING A POLYPHENOUS GRAPE EXTRACT
ES2924255T3 (en) Plant extract highly concentrated in safranal, production method and uses thereof
JP2018505866A (en) Multi supplement composition
EP1377273B1 (en) Method for producing an isoflavone concentrate
DE10315025A1 (en) Active ingredient combination of ω3-fatty oils with polyphenol-containing plant extracts and their use
DE60027481T2 (en) Composition for the treatment of chronic venous insufficiency with an extract of leaves of red grapevines
DE602004006860T2 (en) CAPSAICINOID-CONTAINING PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP1028722A1 (en) Pharmaceutically active composition containing artemisinine and/or a derivative of artemisinine
US9034399B2 (en) Dietary compositions for promoting brain health
EP1091659B1 (en) Oral form of administration
EP2282751B1 (en) Compartment-specific plant extract combination of ginkgo biloba extract and ginseng extract having a tandem effect
DE10315026A1 (en) Compositions containing omega-3 fatty acid oils and plant extracts
EP1305013A1 (en) Preparation with vascular protective and anti-oxidative effect and use thereof
EP1608345A1 (en) Capsules with delayed release of the capsule contents for oral administration
JP2009196967A (en) Agent for increasing relative quantity of polyunsaturated fatty acid in blood, and pharmaceutical composition, quasi-drug, cosmetics, edible composition and animal feed containing the agent
WO2004078189A1 (en) Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders
EP1541037A1 (en) Oral composition containing extracts of Passiflora incarnata
LU500687B1 (en) NUTRITIONAL OR DIETICAL COMPOSITION
DE102011052708A1 (en) Stabilizing photolabile active substances, which are water-soluble and fat-soluble vitamins e.g. Vitamin A, in food and feed by polyphenols benzoic acid derivatives, cinnamic acid derivatives, or quercetin
DE202009006461U1 (en) Combination of tocotrienols with unsaturated fatty acids as a means of protecting the heart / circulatory system, against cancers, for inhibiting inflammation, for increasing mental performance and against age-related disorders
EP2229168A1 (en) Pharmaceutical composition for treating malaria
WO2022162597A1 (en) Combinations of scutellaria extracts with citrus bergamia or cynara cardunculus extracts and formulations containing them
DE202023103890U1 (en) Amla fruit extract and nutrient composition containing the same

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee